+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Toxoplasma Gondii Recombinant Antigen Market - Global Forecast to 2030- Product Image
Toxoplasma Gondii Recombinant Antigen Market - Global Forecast to 2030- Product Image
New

Toxoplasma Gondii Recombinant Antigen Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6080705
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Toxoplasma gondii remains a globally pervasive protozoan parasite, presenting significant challenges across human and veterinary health. Recombinant antigens have emerged as essential tools, enabling precise detection, targeted research applications, and the development of novel vaccines and therapeutics. In recent years, the recombinant antigen segment has advanced rapidly, driven by improvements in protein expression methods, purification technologies, and analytical assays. As diagnostic laboratories demand higher sensitivity and specificity, the transition from native to recombinant antigens has unlocked consistent supply chains and enhanced lot-to-lot reproducibility. Concurrently, research institutes leverage these molecular tools to investigate host-pathogen interactions and to expedite drug discovery efforts. Vaccine candidates formulated with recombinant antigens promise safer immunogenic profiles, reducing the risk associated with whole-pathogen approaches. This introduction establishes the context for understanding the dynamics shaping the Toxoplasma gondii recombinant antigen market, from technological innovations to regulatory influences, and sets the stage for exploring shifts, regional nuances, and strategic imperatives that industry leaders must navigate.

Key Transformative Shifts in Recombinant Antigen Development

The recombinant antigen sector has experienced transformative shifts, spurred by the emergence of advanced expression platforms and evolving diagnostic priorities. Cell-based expression systems, including those utilizing bacterial, insect, mammalian and yeast hosts, now deliver higher yields and enhanced post-translational fidelity. Simultaneously, cell-free expression systems are enabling rapid antigen prototyping, significantly shortening development timelines. In diagnostics, laboratories are migrating from serological assays toward molecular tests that harness Loop-Mediated Isothermal Amplification and Polymerase Chain Reaction, demanding antigens with refined epitope presentation. On the research front, collaborations between academic institutes and pharmaceutical companies are accelerating vaccine design and therapeutic screening, while the expansion of veterinary clinics underscores a growing emphasis on zoonotic surveillance. The proliferation of liquid and lyophilized formats caters to diverse logistical requirements, and segmentation by source-eukaryotic versus prokaryotic-reflects the quest for antigen authenticity against production efficiency. As demand for gender- and age-specific diagnostics emerges, sex- and age-stratified studies are influencing antigen selection. Together, these trends are reshaping competitive dynamics and elevating performance expectations across the value chain.

Cumulative Impact of United States Tariffs on 2025 Operations

The cumulative impact of recent United States tariffs has reverberated across the recombinant antigen supply chain, affecting costs, sourcing strategies and competitive positioning. Tariffs imposed on select laboratory consumables and raw materials have increased production expenses for bacterial and viral expression systems, prompting some manufacturers to shift toward domestic suppliers or to diversify procurement across the Americas and the Asia-Pacific. Diagnostics laboratories reliant on imported antigens have faced inventory disruptions, accelerating adoption of local recombinant antigen production in academic and proprietary research facilities. Pharmaceutical companies and research laboratories are recalibrating budgets to accommodate higher input costs, while veterinary clinics are evaluating economic range and premium products to balance accessibility with performance. Despite these headwinds, some entities are leveraging budget-friendly options by negotiating indirect sales agreements and optimizing distribution channels. Additionally, collaborative partnerships have emerged as a strategic response, with contract research organizations offering bundled antigen supply and assay development services. Overall, the tariff landscape is compelling stakeholders to reexamine their sourcing models, strengthen regional supply resilience and pursue cost-optimization through technological innovation.

Deep Dive into Segmentation Insights Shaping Strategic Focus

In examining market segmentation, product type distinctions between native Toxoplasma gondii antigens and recombinant variants underscore the latter’s growing prominence, driven by consistent quality and scalability. Application segmentation reveals that diagnostics continues to dominate, with molecular testing methodologies such as PCR and LAMP complementing traditional serological approaches including ELISA and IFA, while research purposes harness antigens for immunological assays and pathogenesis studies. The therapeutics segment is gaining traction as antigen-based screening accelerates drug discovery, and vaccine development initiatives are leveraging recombinant proteins to craft safer immunogens. End-user segmentation spans academic and research institutes that pioneer assay development, hospitals and clinics that integrate diagnostics into patient care, pharmaceutical companies investing in R&D pipelines, research laboratories focused on mechanistic studies, and veterinary clinics monitoring zoonotic transmission. Technological platforms bifurcate into cell-based expression systems-encompassing bacterial, insect, mammalian and yeast hosts-and cell-free systems that expedite antigen design iterations. Form preferences oscillate between liquid reagents for rapid use and lyophilized formats for extended shelf life. Source considerations cover eukaryotic and prokaryotic origins, the latter including bacterial and viral constructs. Demographic segmentation by sex and age group ensures relevance in female versus male immunoprofiling and in adult, pediatric or geriatric applications. Finally, distribution channels divide into direct and indirect sales, while pricing strategy spans budget-friendly options, an economic range and premium products aligned with performance tiers.

Key Regional Insights Across Major Geographies

Regional dynamics exhibit distinct patterns across the Americas, where well-established biopharmaceutical hubs and government-funded surveillance programs drive broad adoption of recombinant antigens in both human and veterinary health. In Europe, Middle East & Africa, stringent regulatory frameworks and growing public-private partnerships bolster assay standardization and vaccine research, while emerging markets within the region present opportunities for cost-effective production and distribution innovations. The Asia-Pacific region is characterized by rapid expansion in academic and commercial biotech sectors, with robust investments in cell-based and cell-free expression platforms and an increasing number of contract manufacturing facilities optimizing liquid and lyophilized antigen formats for global distribution. Supply chain resilience is fortified through multi-regional sourcing strategies, and end-user demand is propelled by heightened awareness of zoonotic risks and the integration of advanced molecular diagnostics into public health initiatives. Collectively, these regional nuances highlight the imperative for adaptable commercialization strategies and tailored offerings that align with local regulatory, economic and infrastructure landscapes.

Leading Companies Driving Market Evolution

Competitive landscapes are shaped by leading players vying for market share through product innovation, strategic partnerships and expanded service offerings. Abcam plc positions itself with a diverse recombinant antigen portfolio and collaborative research support, while Bio-Rad Laboratories, Inc. emphasizes integrated assay kits and quality management systems. Creative Diagnostics differentiates through custom antigen design and contract testing services, and GenScript Biotech Corporation leverages proprietary expression technologies to optimize yield. Merck KGaA (Sigma-Aldrich) brings extensive reagent catalogs and regulatory expertise, whereas Novus Biologicals, LLC focuses on niche research applications and assay validation. ProSpec-Tany Technogene Ltd. excels in rapid turnaround times and flexible scale-up options, and QIAGEN N.V. integrates antigen supply with molecular diagnostics platforms. Sino Biological Inc. offers a broad range of cell-based and cell-free derived proteins, and Thermo Fisher Scientific Inc. rounds out the field with global distribution capabilities and comprehensive technical support. Each of these organizations is investing in next-generation antigen expression, purification workflows and quality control measures to meet escalating performance benchmarks and to secure long-term partnerships across diagnostics, research and therapeutic arenas.

Actionable Recommendations for Industry Leaders

Industry leaders should capitalize on emerging opportunities by prioritizing investment in cell-free expression workflows to accelerate antigen development cycles and to reduce dependency on complex cell-based systems. Establishing regional manufacturing hubs and securing strategic alliances can mitigate tariff-induced cost pressures and enhance supply chain resilience across the Americas, Europe, Middle East & Africa, and Asia-Pacific. Companies must expand their product portfolios across liquid and lyophilized formats, ensuring compatibility with direct sales and indirect distribution channels to address diverse end-user needs in hospitals, veterinary clinics and research laboratories. Implementing tiered pricing strategies-ranging from budget-friendly options to premium products-will broaden market access while preserving margins in high-end segments. Furthermore, aligning antigen design with specific diagnostic modalities, such as LAMP and PCR, and with serological assays like ELISA and IFA will reinforce clinical validity and accelerate adoption by diagnostic laboratories. Engaging academic institutes through collaborative research grants and co-development programs can foster innovation in vaccine development and therapeutic screening, while targeted outreach to pharmaceutical companies will drive custom antigen projects. By embracing these action plans, industry players can navigate regulatory landscapes, manage cost volatility, and strengthen their competitive positioning.

Conclusion: Positioning for Sustainable Growth

In conclusion, the recombinant antigen sector for Toxoplasma gondii is undergoing significant transformation, driven by technological advances, shifting diagnostic paradigms and evolving global trade dynamics. Recombinant antigens have established themselves as the cornerstone of modern diagnostics, research applications and emerging vaccine strategies, offering consistent quality and scalability over native alternatives. While United States tariffs present short-term challenges, they also catalyze regional manufacturing initiatives and collaborative solutions that bolster supply chain robustness. Detailed segmentation analysis underscores the need for tailored offerings across product types, applications, end-users, technological platforms, forms, sources, demographics, distribution channels and pricing tiers. Regional insights highlight the importance of adaptive commercialization strategies to address diverse regulatory and economic contexts, and company profiles reveal a dynamic competitive environment where innovation and strategic partnerships are paramount. By executing targeted investments, optimizing supply chains and aligning product development with end-user requirements, stakeholders can unlock new growth trajectories and fortify their market presence.

Market Segmentation & Coverage

This research report categorizes the Toxoplasma Gondii Recombinant Antigen Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Native Toxoplasma Gondii Antigens
  • Recombinant Toxoplasma Gondii Antigens
  • Diagnostics
    • Molecular Tests
      • Loop-Mediated Isothermal Amplification (LAMP)
      • Polymerase Chain Reaction (PCR)
    • Serological Tests
      • Enzyme-Linked Immunosorbent Assay (ELISA)
      • Indirect Immunofluorescence Assay (IFA)
  • Research Purposes
  • Therapeutics
  • Vaccine Development
  • Academic & Research Institutes
  • Hospitals & Clinics
  • Pharmaceutical Companies
  • Research Laboratories
  • Veterinary Clinics
  • Cell-Based Expression Systems
    • Bacterial Expression Systems
    • Insect Cell Expression Systems
    • Mammalian Cell Expression Systems
    • Yeast Expression Systems
  • Cell-Free Expression Systems
  • Liquid
  • Lyophilized
  • Eukaryotic Source
  • Prokaryotic Source
    • Bacterial
    • Viral
  • Female
  • Male
  • Adult
  • Geriatric
  • Pediatric
  • Direct Sales
  • Indirect Sales
  • Budget-Friendly Options
  • Economic Range
  • Premium Products

This research report categorizes the Toxoplasma Gondii Recombinant Antigen Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Toxoplasma Gondii Recombinant Antigen Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abcam plc
  • Bio-Rad Laboratories, Inc.
  • Creative Diagnostics
  • GenScript Biotech Corporation
  • Merck KGaA (Sigma-Aldrich)
  • Novus Biologicals, LLC
  • ProSpec-Tany Technogene Ltd.
  • QIAGEN N.V.
  • Sino Biological Inc.
  • Thermo Fisher Scientific Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Toxoplasma Gondii Recombinant Antigen Market, by Product Type
8.1. Introduction
8.2. Native Toxoplasma Gondii Antigens
8.3. Recombinant Toxoplasma Gondii Antigens
9. Toxoplasma Gondii Recombinant Antigen Market, by Application
9.1. Introduction
9.2. Diagnostics
9.2.1. Molecular Tests
9.2.1.1. Loop-Mediated Isothermal Amplification (LAMP)
9.2.1.2. Polymerase Chain Reaction (PCR)
9.2.2. Serological Tests
9.2.2.1. Enzyme-Linked Immunosorbent Assay (ELISA)
9.2.2.2. Indirect Immunofluorescence Assay (IFA)
9.3. Research Purposes
9.4. Therapeutics
9.5. Vaccine Development
10. Toxoplasma Gondii Recombinant Antigen Market, by End-Users
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Hospitals & Clinics
10.4. Pharmaceutical Companies
10.5. Research Laboratories
10.6. Veterinary Clinics
11. Toxoplasma Gondii Recombinant Antigen Market, by Technological Platform
11.1. Introduction
11.2. Cell-Based Expression Systems
11.2.1. Bacterial Expression Systems
11.2.2. Insect Cell Expression Systems
11.2.3. Mammalian Cell Expression Systems
11.2.4. Yeast Expression Systems
11.3. Cell-Free Expression Systems
12. Toxoplasma Gondii Recombinant Antigen Market, by Form
12.1. Introduction
12.2. Liquid
12.3. Lyophilized
13. Toxoplasma Gondii Recombinant Antigen Market, by Source
13.1. Introduction
13.2. Eukaryotic Source
13.3. Prokaryotic Source
13.3.1. Bacterial
13.3.2. Viral
14. Toxoplasma Gondii Recombinant Antigen Market, by Sex
14.1. Introduction
14.2. Female
14.3. Male
15. Toxoplasma Gondii Recombinant Antigen Market, by Age Group
15.1. Introduction
15.2. Adult
15.3. Geriatric
15.4. Pediatric
16. Toxoplasma Gondii Recombinant Antigen Market, by Distribution Channel
16.1. Introduction
16.2. Direct Sales
16.3. Indirect Sales
17. Toxoplasma Gondii Recombinant Antigen Market, by Pricing Strategy
17.1. Introduction
17.2. Budget-Friendly Options
17.3. Economic Range
17.4. Premium Products
18. Americas Toxoplasma Gondii Recombinant Antigen Market
18.1. Introduction
18.2. Argentina
18.3. Brazil
18.4. Canada
18.5. Mexico
18.6. United States
19. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market
19.1. Introduction
19.2. Australia
19.3. China
19.4. India
19.5. Indonesia
19.6. Japan
19.7. Malaysia
19.8. Philippines
19.9. Singapore
19.10. South Korea
19.11. Taiwan
19.12. Thailand
19.13. Vietnam
20. Europe, Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market
20.1. Introduction
20.2. Denmark
20.3. Egypt
20.4. Finland
20.5. France
20.6. Germany
20.7. Israel
20.8. Italy
20.9. Netherlands
20.10. Nigeria
20.11. Norway
20.12. Poland
20.13. Qatar
20.14. Russia
20.15. Saudi Arabia
20.16. South Africa
20.17. Spain
20.18. Sweden
20.19. Switzerland
20.20. Turkey
20.21. United Arab Emirates
20.22. United Kingdom
21. Competitive Landscape
21.1. Market Share Analysis, 2024
21.2. FPNV Positioning Matrix, 2024
21.3. Competitive Analysis
21.3.1. Abcam plc
21.3.2. Bio-Rad Laboratories, Inc.
21.3.3. Creative Diagnostics
21.3.4. GenScript Biotech Corporation
21.3.5. Merck KGaA (Sigma-Aldrich)
21.3.6. Novus Biologicals, LLC
21.3.7. ProSpec-Tany Technogene Ltd.
21.3.8. QIAGEN N.V.
21.3.9. Sino Biological Inc.
21.3.10. Thermo Fisher Scientific Inc.
22. ResearchAI
23. ResearchStatistics
24. ResearchContacts
25. ResearchArticles
26. Appendix
List of Figures
FIGURE 1. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET MULTI-CURRENCY
FIGURE 2. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET MULTI-LANGUAGE
FIGURE 3. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 22. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 24. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2024 VS 2030 (%)
FIGURE 26. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 30. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 36. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY NATIVE TOXOPLASMA GONDII ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RECOMBINANT TOXOPLASMA GONDII ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY INDIRECT IMMUNOFLUORESCENCE ASSAY (IFA), BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RESEARCH PURPOSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY INSECT CELL EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-FREE EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY EUKARYOTIC SOURCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY INDIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY BUDGET-FRIENDLY OPTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ECONOMIC RANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PREMIUM PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 106. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 109. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 110. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 111. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 112. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 113. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 114. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 115. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 116. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 117. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 118. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 119. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 121. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 128. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 129. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 130. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 131. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 132. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 133. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 183. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 186. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 187. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 188. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 189. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 190. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 191. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 192. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 193. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 194. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 195. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 198. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 201. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 202. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 203. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 204. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 205. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 206. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 207. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 208. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 209. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 210. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 211. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 213. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 216. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 217. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 218. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 219. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 228. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 231. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 232. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 233. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 234. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 235. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 236. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 237. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 238. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 239. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 240. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 241. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 243. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 244. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 246. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 247. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 248. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 249. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 250. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 251. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 252. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 261. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 262. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 263. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 264. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 265. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 266. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 267. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 268. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 269. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 270. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 271. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 273. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 276. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 277. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEROLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 278. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 279. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGICAL PLATFORM, 2018-2030 (USD MILLION)
TABLE 280. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CELL-BASED EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
TABLE 281. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 282. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 283. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PROKARYOTIC SOURCE, 2018-2030 (USD MILLION)
TABLE 284. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY SEX, 2018-2030 (USD MILLION)
TABLE 285. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. SINGAPORE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DISTRIBUTION CHANNEL,

Companies Mentioned

  • Abcam plc
  • Bio-Rad Laboratories, Inc.
  • Creative Diagnostics
  • GenScript Biotech Corporation
  • Merck KGaA (Sigma-Aldrich)
  • Novus Biologicals, LLC
  • ProSpec-Tany Technogene Ltd.
  • QIAGEN N.V.
  • Sino Biological Inc.
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Related Reports

Toxoplasmosis Treatment Drugs Market Report 2025 - Product Image

Toxoplasmosis Treatment Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Gastrointestinal Pathogen Testing Market Report 2025 - Product Image

Gastrointestinal Pathogen Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Research-Grade Proteins - Global Strategic Business Report - Product Image

Research-Grade Proteins - Global Strategic Business Report

  • Report
  • 64 Pages
  • Global
From
Recombinant Proteins - Global Strategic Business Report - Product Image

Recombinant Proteins - Global Strategic Business Report

  • Report
  • 62 Pages
  • Global
From
Custom Polyclonal Antibody Production Service Market - Global Forecast to 2030 - Product Image

Custom Polyclonal Antibody Production Service Market - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.